Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Essai préclinique")

Filter

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 1824

  • Page / 73
Export

Selection :

  • and

Technetium-99m galactosyl-neoglycoalbumin: preparation and preclinical studiesVERA, V. R; STADALNIK, R. C; KROHN, K. A et al.Journal of nuclear medicine. 1985, Vol 26, Num 10, pp 1157-1167, issn 0097-9058Article

Strategies for improving drug development in the early phaseGRIGOLEIT, H.-G.Pharmazeutische Industrie. 1984, Vol 46, Num 5, pp 521-525, issn 0031-711XArticle

Nephrectomized and Hepatectomized Animal Models as Tools in Preclinical PharmacokineticsVESTERGAARD, Bill; AGERSØ, Henrik; LYKKESFELDT, Jens et al.Basic & clinical pharmacology & toxicology (Print). 2013, Vol 113, Num 2, pp 75-86, issn 1742-7835, 12 p.Article

Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directionsVENDITTI, J. M; WESLEY, R. A; PLOWMAN, J et al.Advances in pharmacology and chemotherapy. 1984, Vol 20, pp 1-20, issn 0065-3144Article

Comparative preclinical pharmacokinetic and metabolic studies of the Combretastatin prodrugs Combretastatin A4 phosphate and A1 phosphateKIRWAN, Ian G; LOADMAN, Paul M; SWAINE, David J et al.Clinical cancer research. 2004, Vol 10, Num 4, pp 1446-1453, issn 1078-0432, 8 p.Article

Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441YAN ZHAO; THOMAS, Huw D; BATEY, Michael A et al.Cancer research (Baltimore). 2006, Vol 66, Num 10, pp 5354-5362, issn 0008-5472, 9 p.Article

The preclinical screening laboratory: evaluation of immunomodulatory and therapeutic properties of biological response modifiersTALMADGE, J. E; HERBERMAN, R. B.Cancer treatment reports. 1986, Vol 70, Num 1, pp 171-182, issn 0361-5960Article

The preclinical new drug research program of the National Cancer Institute = Le programme de recherche préclinique de nouveaux produits du National Cancer InstituteDRISCOLL, J. S.Cancer treatment reports. 1984, Vol 68, Num 1, pp 63-76, issn 0361-5960Article

PRECLINICAL TOXICOLOGICAL TESTING AND SAFEGUARDS IN CLINICAL TRIALSGRAHAME SMITH DG.1982; EUR. J. CLIN. PHARMACOL.; ISSN 0031-6970; DEU; DA. 1982; VOL. 22; NO 1; PP. 1-6Article

SYMPOSIUM "MOXALACTAM": EXPERIENCE FRANCAISE, EVALUATION PRE-CLINIQUE ET THERAPEUTIQUE, PARIS, LE 27 OCTOBRE 19811983; SEMAINE DES HOPITAUX; ISSN 0037-1777; FRA; DA. 1983; VOL. 59; NO 26; PP. 1943-2004; ABS. ENG; BIBL. DISSEM.Conference Paper

Klinisch-pharmakologische Aspekte zur Beschleunigung des Drug Development-Prozesses von der Präklinik zur Klinik. 2. Mitteilung: Erfolgversprechende Strategien = Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase: 2nd communication: Promising strategiesKUHLMANN, Jochen.Arzneimittel-Forschung. 2004, Vol 54, Num 6, pp 307-313, issn 0004-4172, 7 p.Article

The National Cancer Institute antitumor drug discovery program, current and future perspectives: a commentary = Le programme de recherche des drogues antitumorales du National Cancer Institute, perspectives future et couranteVENDITTI, J. M.Cancer treatment reports. 1983, Vol 67, Num 9, pp 767-772, issn 0361-5960Article

Regulatory considerations on the role of general pharmacology studies in the development of therapeutic agentsPROAKIS, A. G.Drug development research. 1994, Vol 32, Num 4, pp 233-236, issn 0272-4391Conference Paper

Etoposide (VP-16-213). Current status of an active anticancer drugÓDWYER, P. J; LEYLAND-JONES, B; ALONSO, M. T et al.The New England journal of medicine. 1985, Vol 312, Num 11, pp 692-700, issn 0028-4793Article

Preclinical Characterization of SGN-70, a Humanized Antibody Directed against CD70MCEARCHERN, Julie A; SMITH, Leia M; GREWAL, Iqbal S et al.Clinical cancer research (Print). 2008, Vol 14, Num 23, pp 7763-7772, issn 1078-0432, 10 p.Article

Klinisch-pharmakologische Aspekte zur Beschleunigung des Drug Development-Prozesses von der Präklinik zur Klinik 1. Mitteilung: Beitrag der klinischen Pharmakologie = Clinical-pharmacological aspects to accelerate the development process from the preclinical to the clinical phase / 1st communication: The contribution of clinical pharmacologyKUHLMANN, Jochen.Arzneimittel-Forschung. 2004, Vol 54, Num 5, pp 251-258, issn 0004-4172, 8 p.Article

Nouveaux concepts applicables à l'évaluation préclinique de la sécurité des médicaments = New concepts for the preclinical safety evaluation of drugsDESCOTES, J; RAVEL, G; VIAL, T et al.La Lettre du pharmacologue (Boulogne). 2003, Vol 17, Num 5, pp 165-168, issn 0984-452X, 4 p.Article

Preclinical restenosis models : Challenges and successesTOUCHARD, Arturo G; SCHWARTZ, Robert S.Toxicologic pathology. 2006, Vol 34, Num 1, pp 11-18, issn 0192-6233, 8 p.Conference Paper

Unresolved issues in combination chemotherapyWITTES, R. E; GOLDIN, A.Cancer treatment reports. 1986, Vol 70, Num 1, pp 105-125, issn 0361-5960Article

Antihyperlipidemic properties of β-pyridylcarbinol. A review of preclinical studiesCOHEN, M.Life sciences (1973). 1985, Vol 37, Num 21, pp 1949-1961, issn 0024-3205Article

Preclinical predictors of clinical safety : Opportunities for improvementSISTARE, F. D; DEGEORGE, J. J.Clinical pharmacology and therapeutics. 2007, Vol 82, Num 2, pp 210-214, issn 0009-9236, 5 p.Article

Abstracts/Research Society on Alcoholism meeting, June 1-5, 1988, Charleston, SC, USAAlcoholism, clinical and experimental research. 1988, Vol 12, Num 2, pp 302-348, issn 0145-6008Conference Proceedings

Preclinical pharmacokinetics of benznidazoleWORKMAN, P; WHITE, R. A. S; WALTON, M. I et al.British journal of cancer. 1984, Vol 50, Num 3, pp 291-303, issn 0007-0920Article

Shh pathway activity is down-regulated in cultured medulloblastoma cells : Implications for preclinical studiesSASAI, Ken; ROMER, Justyna T; LEE, Youngsoo et al.Cancer research (Baltimore). 2006, Vol 66, Num 8, pp 4215-4222, issn 0008-5472, 8 p.Article

Preclinical Experiments on the Release Behavior of Biodegradable Nanofibrous Multipharmaceutical Membranes in a Model of Four-Wall Intrabony DefectCHEN, Dave Wei-Chih; LEE, Fu-Ying; LIAO, Jun-Yi et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 1, pp 9-14, issn 0066-4804, 6 p.Article

  • Page / 73